Search

for
Search:

Learn

0 / 0 results

— no results

Research

1 / 1 results

Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women

research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women

3 citations, May 2018 in “Reproductive Sciences”

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Community Join

3 / 3 results

community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer

in Research/Science 51 upvotes 6 months ago

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

community Somebody has gotta try this- HMI-115 reference anti-body

in Treatment 14 upvotes 1 year ago

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

community hmi115 is coming. Prepare yourselves for what's coming

in Technology 104 upvotes 1 year ago

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.